Recombinant thrombomodulin - PAION

Drug Profile

Recombinant thrombomodulin - PAION

Alternative Names: Solulin

Latest Information Update: 11 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berlex Biosciences
  • Developer PAION
  • Class Anti-inflammatories; Anticoagulants; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Haemophilia; Stroke; Thrombosis

Most Recent Events

  • 11 Feb 2015 Suspended - Phase-I for Haemophilia (Adjunctive treatment) in Germany (IV) prior to February 2015
  • 11 Feb 2015 Suspended - Phase-I for Stroke (In volunteers) in Germany (IV) prior to February 2015
  • 11 Feb 2015 Suspended - Phase-I for Thrombosis (In volunteers) in Germany (IV) prior to February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top